Chimeric Therapeutics Limited (ASX:CHM) Financings
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Convertible notes with associated warrants Tranche closed: A$650,000 raised Use of proceeds: Support the ongoing Phase 1/2 clinical trial activities and general working capital | Jul 31, 2026 | US$456,561 |
| Private placement of fully paid ordinary shares with 1-for-1 attaching options Announced: A$4.4M · A$0.003 a share · Warrants at A$0.005 · PAC Partners Securities Pty Ltd +1 Dealers: PAC Partners Securities Pty Ltd (co-lead), Taylor Collison Limited (co-lead) Buyers: US-based family office (US$2 M (~A$3 M) commitment) Use of proceeds: CHM CDH17 CAR-T trial to end of Phase 1, CORE-NK clinical programs, working capital and offer costs | Dec 23, 2025 | US$2.94M |
| Convertible note Announced: A$4M Buyers: US institutional investor (A$4 M via Convertible Note) Use of proceeds: Fund the CHM CDH17 CAR-T trial through Phase 1, including next patient cohort at an increased dose | Dec 23, 2025 | US$2.68M |
| Rights offering of new fully paid ordinary shares with attaching options Closed: A$1M raised · 1 new attaching option for every New Share issued · PAC Partners +1 Dealers: PAC Partners (co-lead), Taylor Collison (co-lead) Use of proceeds: Further runway to progress the company's programs | Apr 24, 2025 | US$639,490 |